The role of the novel HIV fusion inhibitor enfuvirtide in multiresistant vertical AIDS treated since birth

Italian Journal of Pediatrics

Volumn 31, Issue 2, 2005, Pages 130-132

  Manfredi, Roberto ^a   Calza, L ^a   Chiodo, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

AIDS; Efficacy; Enfuvirtide; Fusion inhibitors; HIV infection; Multiresistant infection; Salvage therapy; Tolerability

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL PRACTICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; MALE; MULTIDRUG RESISTANCE; SALVAGE THERAPY; VERTICAL TRANSMISSION;

EID: 23644449544     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Englund JA, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R, et al. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J 2004;23:15-22.
2. Pillay D, Walker AS, Gibb DM, De Rossi A, Kaye S, Ait-Khaled M, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002;186:617-25.
3. Neely M, Kovacs A. Management of antiretroviral therapy in neonates, children, and adolescents. Curr Infect Dis Rep 2003;5:521-30.
4. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA. JAMA 2004;292:251-65.
5. Stolk LM, Luers JF. Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Pharm World Sci 2004;26:133-6.
6. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004;5(Suppl 2):61-86.
7. McKinney RE, Cunningham CK. Newer treatments for HIV in children. Curr Opin Pediatr 2004;16:76-9.
8. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004;23:713-8.
9. Greenberg M, Cammack N, Salgo M, Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004;14:321-37.
10. Dando TM, Perry CM. Enfuvirtide. Drugs 2003;63:2755-66.
11. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004;24:198-211.
12. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, et al. Population pharmacokinetic of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationship. Clin Pharmacol Ther 2003;74:569-80.
13. Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23:1137-41.
14. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
15. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New Engl J Med 2003;348:2186-95.